Superselective Adrenal Arterial Embolization Versus Oral Spironolactone for Treatment of Idiopathic Hyperaldosteronism
Status:
RECRUITING
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
Idiopathic hyperaldosteronism (IHA) represents about 65% of primary hyperaldosteronism cases. Although mineralocorticoid receptor antagonists (MRAs) are the standard first-line treatment, they are often limited by adverse effects. Superselective adrenal artery embolization (SAAE) has been utilized for IHA over the last decade, yet comparative studies against MRAs are lacking. The objective of this study is to compare the safety and efficacy of SAAE and MRA to determine the feasibility of SAAE in treating IHA.
Phase:
NA
Details
Lead Sponsor:
Chinese Academy of Medical Sciences, Fuwai Hospital
Collaborators:
First Affiliated Hospital of Chengdu Medical College Second Affiliated Hospital of Nanchang University